Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 11171-11180 Newer>

The Motley Fool December 12, 2005 Nathan Parmelee	Not All Debt Is Evil Debt-free companies can have their virtues, but debt has an undeserved bad rap with individual investors. When you find a company with debt, dig into the details.
The Motley Fool December 12, 2005 Brian Gorman	Kellogg's Trans-Fat Tradeoff Kellogg's use of a new soybean oil could constrain its ability to sell overseas due to European mistrust of genetically modified products. Investors, take note.
The Motley Fool December 12, 2005 Stephen D. Simpson	Heavy Breathing for Myogen Positive data from a phase 3 drug study sends shares of this biotech much higher.
The Motley Fool December 12, 2005 Rick Aristotle Munarriz	Morningstar Gets Brighter Financial research specialist Morningstar intends to buy Ibbotson Associates. Investors, take note.
The Motley Fool December 12, 2005 Seth Jayson	Never a Cloud for Google When investors see nothing but sunshine ahead, watch your wallet. When a $120 billion company with a P/E near 100 continues flying on both good news and bad, something's just not right.
The Motley Fool December 12, 2005 Tim Beyers	Music Biz Grumbles Again Innovations from the satellite sector incite more whining from the recording industry. The truth is that the music biz and satellite radio need each other. Badly. Investors, take note.
The Motley Fool December 12, 2005 Alyce Lomax	Yahoo!'s Delicious Deal The Internet giant snaps up yet another Web innovator. Yahoo! may have its work cut out for it, but the company's investors are likely glad that it is trying to spearhead some of the Web's hottest trends.
The Motley Fool December 12, 2005 Steven Mallas	The Lion, the Chicken, and the Dividend Will Narnia's success cause Disney's stock to magically rise?
The Motley Fool December 12, 2005 Shannon Zimmerman	Genentech: Good Company, Bad Investment Stock valuations in the biotech industry are expensive in general, but on a trailing-12-month basis, Genentech's price-to-earnings, price-to-book, price-to-sales, and price-to-cash flow figures all dwarf those of the broader market. If the price isn't right, buyer beware.
The Motley Fool December 12, 2005 Stephen D. Simpson	Be Ready for Market Stupidity Despite being composed of some very intelligent people, the market does stupid things from time to time. As an investor, you must decide for yourself whether "bad news" is really that bad.
<Older 11171-11180 Newer> Return to current articles.